Drugs / RC88
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05804526 | Jul 2023 → May 2025 | cancer | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05508334 | Jan 2023 → Nov 2025 | cancer | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04175847 | Apr 2020 → Dec 2025 | cancer | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06173037 | Jan 2024 → Dec 2025 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | RemeGen Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06016062 Background | Sep 2023 → Dec 2025 overdue | cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC88 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06173037 ↗ |
| Route | Intravenous | “intravenous infusion of RC88” NCT05508334 ↗ |